— Know what they know.
Not Investment Advice

ERAS NASDAQ

Erasca, Inc.
1W: +3.4% 1M: -10.0% 3M: -21.8% YTD: +310.6% 1Y: +567.0% 3Y: +579.3% 5Y: -23.4%
$14.74
+0.16 (+1.10%)
 
Weekly Expected Move ±7.5%
$13 $14 $15 $16 $17
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 32 · $5.1B mcap · 223M float · 2.15% daily turnover · Short 67% of daily vol

Income Trends

Revenue
$0 +0.0% ▲
Gross Profit
-$3M +0.0% ▲
Operating Income
-$131M +26.8% ▲
Net Income
-$125M +23.0% ▲
EPS (Diluted)
$-0.44 +36.2% ▲
EBITDA
-$128M +16.3% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
Revenue$0$0$0$0$0
YoY Growth+0.0%+0.0%+0.0%+0.0%+0.0%
Cost of Revenue$829K$3M$4M$0$3M
Gross Profit-$829K-$3M-$4M$0-$3M
Gross Margin—————
R&D Expenses$74M$112M$104M$115M$93M
SG&A Expenses$23M$33M$38M$42M$39M
Operating Expenses$124M$245M$138M$180M$128M
Operating Income-$125M-$247M-$142M-$180M-$131M
Operating Margin—————
Interest Expense$0$201M$0$0$0
Income Before Tax-$123M-$243M-$125M-$162M-$125M
Tax Expense$0$0$0$0$0
Net Income-$123M-$243M-$125M-$162M-$125M
Net Margin—————
EPS (Diluted)$-1.03$-1.99$-0.83$-0.69$-0.44
EBITDA-$122M-$240M-$121M-$153M-$128M
Shares Outstanding119M122M150M234M284M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms